JP2024500378A - 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 - Google Patents

多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 Download PDF

Info

Publication number
JP2024500378A
JP2024500378A JP2023535992A JP2023535992A JP2024500378A JP 2024500378 A JP2024500378 A JP 2024500378A JP 2023535992 A JP2023535992 A JP 2023535992A JP 2023535992 A JP2023535992 A JP 2023535992A JP 2024500378 A JP2024500378 A JP 2024500378A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
halogen
inhibitor
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500378A5 (enExample
Inventor
ホイット，スコット，ブライアン
トーマス，クレイグ，ジョセフ
スターチナウスキー，ダニエル，ティー．
サッター，パトリック，ジョセフ
タワ，グレゴリー，ジェームス
フィノッキオ，クリス，ジェームス
ローゼンバウム，ジャン，スーザン
マルドナド，ガブリエル グラシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children S Hospital Medical Center
Original Assignee
Children S Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children S Hospital Medical Center filed Critical Children S Hospital Medical Center
Publication of JP2024500378A publication Critical patent/JP2024500378A/ja
Publication of JP2024500378A5 publication Critical patent/JP2024500378A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023535992A 2020-12-15 2021-12-15 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用 Pending JP2024500378A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125654P 2020-12-15 2020-12-15
US63/125,654 2020-12-15
PCT/US2021/063567 WO2022132936A1 (en) 2020-12-15 2021-12-15 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2024500378A true JP2024500378A (ja) 2024-01-09
JP2024500378A5 JP2024500378A5 (enExample) 2024-12-24

Family

ID=82058056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535992A Pending JP2024500378A (ja) 2020-12-15 2021-12-15 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用

Country Status (9)

Country Link
US (1) US12534469B2 (enExample)
EP (1) EP4262802A4 (enExample)
JP (1) JP2024500378A (enExample)
CN (1) CN116887834A (enExample)
AU (1) AU2021403015A1 (enExample)
CA (1) CA3201690A1 (enExample)
IL (1) IL303709A (enExample)
MX (1) MX2023006937A (enExample)
WO (1) WO2022132936A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
JP2025525322A (ja) * 2022-06-15 2025-08-05 チルドレンズ ホスピタル メディカル センター 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用
AU2024264188A1 (en) * 2023-04-28 2025-11-06 Kurome Therapeutics, Inc. Irak inhibitor free base, salts, and polymorphic forms thereof
WO2025029929A1 (en) * 2023-07-31 2025-02-06 Children's Hospital Medical Center Multi-cyclic irak1 and irak4 inhibiting compounds and uses thereof
WO2025137567A1 (en) * 2023-12-20 2025-06-26 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520887A (ja) * 2008-05-13 2011-07-21 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
JP2019522656A (ja) * 2015-06-24 2019-08-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリール置換のアミノピリジン化合物
CN110835334A (zh) * 2018-08-16 2020-02-25 中国药科大学 吲哚取代唑类化合物及其用途
US20200199123A1 (en) * 2016-08-17 2020-06-25 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33304A (es) * 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
WO2017044623A1 (en) * 2015-09-09 2017-03-16 Lau Warren C Methods, compositions, and uses of novel fyn kinase inhibitors
SG11202005237SA (en) * 2017-12-15 2020-07-29 Pyramid Biosciences Inc 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520887A (ja) * 2008-05-13 2011-07-21 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての縮合窒素含有ヘテロ環およびその組成物
JP2019522656A (ja) * 2015-06-24 2019-08-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリール置換のアミノピリジン化合物
US20200199123A1 (en) * 2016-08-17 2020-06-25 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds
CN110835334A (zh) * 2018-08-16 2020-02-25 中国药科大学 吲哚取代唑类化合物及其用途

Also Published As

Publication number Publication date
CN116887834A (zh) 2023-10-13
US20240124468A1 (en) 2024-04-18
EP4262802A1 (en) 2023-10-25
EP4262802A4 (en) 2024-11-13
WO2022132936A1 (en) 2022-06-23
AU2021403015A1 (en) 2023-08-03
US12534469B2 (en) 2026-01-27
CA3201690A1 (en) 2022-06-23
MX2023006937A (es) 2023-10-13
IL303709A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
JP6348891B2 (ja) Ｃｘｃｒ４受容体アンタゴニスト
RU2665462C2 (ru) Соединения 5-азаиндазола и способы их применения
US12534469B2 (en) Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof
JP2023538242A (ja) 多環式ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
US20250154144A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
US20250368648A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
US12612410B2 (en) Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof
WO2023150601A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
KR20260004307A (ko) 다환성 irak 및 flt3 억제 화합물 및 이의 용도
EP4598539A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
HK40101779A (zh) 多环irak和flt3抑制化合物以及其用途
WO2023250431A9 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2025137567A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
CN118613480A (zh) 多环irak和flt3抑制化合物以及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210